Article
Value Stream Identification in Drug Development: Success Story Deloitte & Boehringer Ingelheim IT Drug Development
Building a Foundation for Successful Product Implementation and Strengthening Business/IT Collaboration
The IT Drug Development management team at Boehringer Ingelheim, in partnership with Deloitte, is embarking on a transformational journey. Leveraging Deloitte's expertise, the team aims to streamline IT operations, optimize business and IT collaboration, and establish a solid foundation to kickstart the new product organization.
Navigating the Pharmaceutical Landscape - Pioneering Product-Centricity
In today's dynamic pharmaceutical landscape, closer collaboration between business and IT in the value creation is crucial for success. This collaborative effort not only optimizes the flow of value creation but also leads to more customer-centric workflows. Given the complexities of the healthcare sector, seamless cooperation between stakeholders is essential for faster time-to-market, improved patient care, and innovative products.
The IT Drug Development management team at Boehringer Ingelheim recognizes the need to shift from project-based to product-centric IT delivery to enhance customer-centricity and improve value delivery. This transition involves aligning IT teams and business units within a product-oriented framework, breaking down handovers, and promoting synergy and unified solution development.
The objective is to establish autonomous product teams aligned with delivering value to customers and stakeholders. This alignment ensures that the organization can be more responsive to requirements and integrate new technologies into the business model faster than today.
From Vision to Reality: Shaping IT Products for Global Drug Development
“One of the key aspects of making this shift is to organize cross-functional teams around our company’s value streams. The IT Drug Development of Boehringer Ingelheim is pursuing this goal by moving from a project-based to a product-centric IT operating model.”
- Alexander Schmalz, Head of IT Development, Boehringer Ingelheim
In the dynamic world of pharmaceutical R&D, aligning teams, workflows and tools around value streams are the linchpin for efficiency and innovation. It's the catalyst for streamlining operations, optimizing resource allocation, and accelerating drug development. Recognizing its key role, the IT Drug Development department at Boehringer Ingelheim has forged a partnership with Deloitte, aiming to harness the power of value stream identification.
What is Value Stream Identification (VSI)?
Value Stream Identification is fundamental to the design of product-centric organizations and centers cross-functional teams around the products, solutions and services that bring value to customers. Instead of traditional department-oriented structures, it focuses on a seamless flow of value, ensuring efficiency and collaboration.
Imagine teams who clearly understand their value add for the customers at every step. That's the essence of Value Stream Identification – creating seamless experiences by mixing diverse talents and ideas.
Together, Boehringer Ingelheim’s IT Drug Development and Deloitte embarked on a journey of collaboration and transformation. Our focus shifted towards shaping IT products that support global drug development, following five key stages :
- Business and IT Alignment: Collaboratively aligning on problem statements and transformation objectives for the affected value stream.
- Value Stream Landscape Definition: Definition of an overarching Value Stream Landscape based on business capabilities.
- Value Stream Identification: Identification of key steps and the value-adding IT activities within the individual value streams.
- Product Team Definition: Deriving Product Teams based on detailed value stream analysis, considering user community, data flow and technology.
- Implementation Roadmap: Defining a 7-30-60-90 days implementation roadmap to sustain the workshop outcomes.
This holistic approach required active participation from both IT and business departments. Deloitte's team worked closely with stakeholders, fostering a collaborative environment where ideas flowed freely. Over six months, we identified 5 business value streams and shaped 13 IT products, with over 60 participants from the US and Germany.
A motivated team to collaborate and embark on the journey.
“Identifying the value streams and IT products helped us a lot in setting a meaningful baseline for implementing the overall product organization. There is still quite a lot of work ahead of us to actually live this, but the foundation is in place. This is an exciting time!”
– Thomas Moll, Head of IT Development for Non-clinical Drug Safety, Boehringer Ingelheim
The Value Stream Identification (VSI) workshops helped to identify and design the digital product landscape. Looking forward, Boehringer’s IT Drug Development remains confident in its ability to leverage its enhanced IT operating model to accelerate product innovation and further streamline operations.
Ihre Ansprechpartnerin
